52.92
1.05 (2.01%)
| Previous Close | 51.87 |
| Open | 51.25 |
| Volume | 140,736 |
| Avg. Volume (3M) | 735,391 |
| Market Cap | 2,287,149,824 |
| Price / Sales | 917.60 |
| Price / Book | 6.17 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2026 |
| Operating Margin (TTM) | -2,852.71% |
| Diluted EPS (TTM) | -2.83 |
| Quarterly Revenue Growth (YOY) | 33.10% |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 15.98 |
| Operating Cash Flow (TTM) | -90.87 M |
| Levered Free Cash Flow (TTM) | -52.44 M |
| Return on Assets (TTM) | -20.04% |
| Return on Equity (TTM) | -28.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Dianthus Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.87% |
| % Held by Institutions | 119.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (Guggenheim, 277.97%) | Buy |
| Median | 130.00 (145.68%) | |
| Low | 81.00 (Jefferies, 53.08%) | Buy |
| Average | 128.22 (142.31%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 77.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 12 Mar 2026 | 103.00 (94.65%) | Buy | 80.32 |
| 10 Mar 2026 | 80.00 (51.19%) | Buy | 86.92 | |
| Baird | 10 Mar 2026 | 132.00 (149.46%) | Buy | 86.92 |
| Clear Street | 10 Mar 2026 | 130.00 (145.68%) | Buy | 86.92 |
| Raymond James | 10 Mar 2026 | 123.00 (132.45%) | Buy | 86.92 |
| HC Wainwright & Co. | 09 Mar 2026 | 130.00 (145.68%) | Buy | 79.23 |
| Oppenheimer | 09 Mar 2026 | 145.00 (174.02%) | Buy | 79.23 |
| Truist Securities | 09 Mar 2026 | 110.00 (107.88%) | Buy | 79.23 |
| 08 Jan 2026 | 63.00 (19.06%) | Buy | 38.12 | |
| Guggenheim | 04 Mar 2026 | 200.00 (277.96%) | Buy | 62.03 |
| Jefferies | 02 Feb 2026 | 81.00 (53.08%) | Buy | 53.18 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARR EDWARD | - | 80.32 | -43,682 | -3,508,538 |
| GARCIA MARINO | - | 80.32 | -122,918 | -9,872,774 |
| RANDHAWA SIMRAT | - | 80.32 | -33,830 | -2,717,226 |
| Aggregate Net Quantity | -200,430 | |||
| Aggregate Net Value ($) | -16,098,538 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 80.32 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GARCIA MARINO | Officer | 12 Mar 2026 | Automatic sell (-) | 122,918 | 80.32 | 9,872,774 |
| GARCIA MARINO | Officer | 12 Mar 2026 | Option execute | 122,918 | - | - |
| RANDHAWA SIMRAT | Officer | 12 Mar 2026 | Automatic sell (-) | 33,830 | 80.32 | 2,717,226 |
| RANDHAWA SIMRAT | Officer | 12 Mar 2026 | Option execute | 33,830 | - | - |
| CARR EDWARD | Officer | 12 Mar 2026 | Automatic sell (-) | 43,682 | 80.32 | 3,508,538 |
| CARR EDWARD | Officer | 12 Mar 2026 | Option execute | 43,682 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 05 Jan 2026 | Announcement | Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 23 Dec 2025 | Announcement | Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |